Real‐life efficacy and safety of elexacaftor/tezacaftor/ivacaftor on severe cystic fibrosis lung disease patients

Abstract Elexacaftor/tezacaftor/ivacaftor (ETI) is a cystic fibrosis (CF) transmembrane conductance regulator modulator, which has shown efficacy in CF patients (≥6 years) with ≥1 Phe508del mutation and a minimal function mutation. In October 2019, ETI became available on compassionate use basis for...

Полное описание

Библиографические подробности

Главные авторы:	Renate Kos, Anne H. Neerincx, Dominic W. Fenn, Paul Brinkman, Rianne Lub, Steffie E. M. Vonk, Jolt Roukema, Monique H. Reijers, Suzanne W. J. Terheggen‐Lagro, Josje Altenburg, Christof J. Majoor, Lieuwe D. Bos, Eric G. Haarman, Anke H. Maitland‐van der Zee, the Amsterdam Mucociliary Clearance Disease (AMCD) Research Group
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2022-12-01
Серии:	Pharmacology Research & Perspectives
Предметы:	cystic fibrosis elexacaftor/tezacaftor/ivacaftor modulators sputum
Online-ссылка:	https://doi.org/10.1002/prp2.1015
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!